WO2000061178A1 - Administration pulmonaire de formulations de poudre seche pour le traitement de l'infecondite - Google Patents

Administration pulmonaire de formulations de poudre seche pour le traitement de l'infecondite Download PDF

Info

Publication number
WO2000061178A1
WO2000061178A1 PCT/US2000/009869 US0009869W WO0061178A1 WO 2000061178 A1 WO2000061178 A1 WO 2000061178A1 US 0009869 W US0009869 W US 0009869W WO 0061178 A1 WO0061178 A1 WO 0061178A1
Authority
WO
WIPO (PCT)
Prior art keywords
fsp
composition
cys
thr
powder
Prior art date
Application number
PCT/US2000/009869
Other languages
English (en)
Inventor
Sudha Nagarajan
John S. Patton
David B. Bennett
Joanne Greene
Hi-Shi Chiang
Cheryl L. M. Stults
Geraldine Venthoye
Darrel Lavern Allen
Benjamin Lee Hughes
Mary Stiff-Torvik
Ronald Keith Wolff
William David Roeder
Original Assignee
Inhale Therapeutics Systems, Inc.
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhale Therapeutics Systems, Inc., Eli Lilly And Company filed Critical Inhale Therapeutics Systems, Inc.
Priority to AU40820/00A priority Critical patent/AU779869B2/en
Priority to EP00920245A priority patent/EP1169053A1/fr
Priority to CA002369262A priority patent/CA2369262A1/fr
Priority to JP2000610510A priority patent/JP2002541213A/ja
Priority to US09/958,722 priority patent/US7112341B1/en
Publication of WO2000061178A1 publication Critical patent/WO2000061178A1/fr
Priority to HK02103235.7A priority patent/HK1042234A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Abstract

La présente invention concerne des compositions stables de poudre sèche de protéine folliculostimulante (FSP) pour une délivrance en aérosol dans le poumon profond, des procédés de préparation et d'administration de telles compositions, ainsi que des procédés de traitement de l'infécondité comportant l'administration de poudres sèches par délivrance pulmonaire dans le poumon profond.
PCT/US2000/009869 1999-04-13 2000-04-13 Administration pulmonaire de formulations de poudre seche pour le traitement de l'infecondite WO2000061178A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU40820/00A AU779869B2 (en) 1999-04-13 2000-04-13 Pulmonary administration of dry powder formulations for treating infertility
EP00920245A EP1169053A1 (fr) 1999-04-13 2000-04-13 Administration pulmonaire de formulations de poudre seche pour le traitement de l'infecondite
CA002369262A CA2369262A1 (fr) 1999-04-13 2000-04-13 Administration pulmonaire de formulations de poudre seche pour le traitement de l'infecondite
JP2000610510A JP2002541213A (ja) 1999-04-13 2000-04-13 不妊症の処置のための乾燥粉末処方物の肺投与
US09/958,722 US7112341B1 (en) 1999-04-13 2000-04-13 Pulmonary administration of dry powder formulations for treating infertility
HK02103235.7A HK1042234A1 (zh) 1999-04-13 2002-04-30 向肺部施加乾粉配方以治療不育症

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12912199P 1999-04-13 1999-04-13
US60/129,121 1999-04-20
US60/130,099 1999-04-20

Publications (1)

Publication Number Publication Date
WO2000061178A1 true WO2000061178A1 (fr) 2000-10-19

Family

ID=22438552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009869 WO2000061178A1 (fr) 1999-04-13 2000-04-13 Administration pulmonaire de formulations de poudre seche pour le traitement de l'infecondite

Country Status (1)

Country Link
WO (1) WO2000061178A1 (fr)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002100378A2 (fr) * 2001-06-09 2002-12-19 Ml Lab Plc Procede
WO2002054868A3 (fr) * 2000-12-21 2003-03-27 Inhale Therapeutic Systems, Inc. Apport pulmonaire d'agents antifongiques polyene
WO2003035051A2 (fr) * 2001-10-19 2003-05-01 Inhale Therapeutic Systems, Inc. Utilisation d'agents sequestrants des protons dans des formulations medicamenteuses
WO2003035028A1 (fr) * 2001-10-19 2003-05-01 Nektar Therapeutics Modulation de la densite de charge pour ameliorer les caracteristiques de proteines sechees par pulverisation
US6630121B1 (en) 1999-06-09 2003-10-07 The Regents Of The University Of Colorado Supercritical fluid-assisted nebulization and bubble drying
EP1223915B1 (fr) * 1999-10-29 2005-12-21 Nektar Therapeutics Compositions de poudre seche a dispersivite amelioree
EP1663151A2 (fr) * 2003-09-15 2006-06-07 Vectura Limited Agents mucoactifs pour le traitement d'une maladie pulmonaire
WO2008132224A3 (fr) * 2007-04-30 2009-03-19 Novo Nordisk As Procédé de déshydratation d'une composition de protéine, composition de protéine déshydratée et composition pharmaceutique contenant la protéine déshydratée
WO2010054403A1 (fr) 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles associés au complément
US7754242B2 (en) 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
WO2010151526A1 (fr) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Anticorps bispécifiques se liant aux protéines du complément
WO2011085343A1 (fr) 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc Biomarqueurs d'effets immunomodulateurs chez des humains traités par des anticorps anti-cd200
WO2011137395A1 (fr) 2010-04-30 2011-11-03 Rother Russell P Anticorps anti-c5a et méthodes pour utiliser les anticorps
US8710001B2 (en) 2006-07-31 2014-04-29 Novo Nordisk A/S PEGylated, extended insulins
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
US9079949B1 (en) 2014-03-07 2015-07-14 Alexion Pharmaceuticals, Inc. Anti-C5 antibodies having improved pharmacokinetics
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
US9688737B2 (en) 2008-03-18 2017-06-27 Novo Nordisk A/S Protease stabilized acylated insulin analogues
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
EP1487411B1 (fr) * 2002-03-20 2019-01-02 Civitas Therapeutics, Inc. Formulations therapeutiques soutenues respirables
US10265385B2 (en) 2016-12-16 2019-04-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
WO2019126536A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Anticorps humanisés anti-cd200 et leurs utilisations
US11365241B2 (en) 2017-07-27 2022-06-21 Alexion Pharmaceuticals, Inc. High concentration anti-C5 antibody formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000128A1 (fr) * 1993-06-24 1995-01-05 Astra Aktiebolag Preparation pour inhalations
WO1996019207A1 (fr) * 1994-12-22 1996-06-27 Astra Aktiebolag Formulations pulverulentes contenant du melezitose en tant que diluant
WO1997041833A1 (fr) * 1996-05-08 1997-11-13 Inhale Therapeutic Systems Compositions dispersibles a base de macromolecules, procedes de preparation et techniques d'utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995000128A1 (fr) * 1993-06-24 1995-01-05 Astra Aktiebolag Preparation pour inhalations
WO1996019207A1 (fr) * 1994-12-22 1996-06-27 Astra Aktiebolag Formulations pulverulentes contenant du melezitose en tant que diluant
WO1997041833A1 (fr) * 1996-05-08 1997-11-13 Inhale Therapeutic Systems Compositions dispersibles a base de macromolecules, procedes de preparation et techniques d'utilisation

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630121B1 (en) 1999-06-09 2003-10-07 The Regents Of The University Of Colorado Supercritical fluid-assisted nebulization and bubble drying
EP1223915B1 (fr) * 1999-10-29 2005-12-21 Nektar Therapeutics Compositions de poudre seche a dispersivite amelioree
US8501240B2 (en) 1999-10-29 2013-08-06 Novartis Ag Compositions comprising an active agent
WO2002054868A3 (fr) * 2000-12-21 2003-03-27 Inhale Therapeutic Systems, Inc. Apport pulmonaire d'agents antifongiques polyene
US7473433B2 (en) 2000-12-21 2009-01-06 Nektar Therapeutics Pulmonary delivery of polyene antifungal agents
WO2002100378A3 (fr) * 2001-06-09 2003-04-10 Ml Lab Plc Procede
WO2002100378A2 (fr) * 2001-06-09 2002-12-19 Ml Lab Plc Procede
WO2003035051A2 (fr) * 2001-10-19 2003-05-01 Inhale Therapeutic Systems, Inc. Utilisation d'agents sequestrants des protons dans des formulations medicamenteuses
WO2003035028A1 (fr) * 2001-10-19 2003-05-01 Nektar Therapeutics Modulation de la densite de charge pour ameliorer les caracteristiques de proteines sechees par pulverisation
WO2003035051A3 (fr) * 2001-10-19 2004-03-11 Inhale Therapeutic Syst Utilisation d'agents sequestrants des protons dans des formulations medicamenteuses
US7754242B2 (en) 2002-03-20 2010-07-13 Alkermes, Inc. Inhalable sustained therapeutic formulations
EP1487411B1 (fr) * 2002-03-20 2019-01-02 Civitas Therapeutics, Inc. Formulations therapeutiques soutenues respirables
EP2277505A2 (fr) * 2003-09-15 2011-01-26 Vectura Limited Agents mucoactifs pour le traitement d'une maladie pulmonaire
EP1663151A2 (fr) * 2003-09-15 2006-06-07 Vectura Limited Agents mucoactifs pour le traitement d'une maladie pulmonaire
US8710001B2 (en) 2006-07-31 2014-04-29 Novo Nordisk A/S PEGylated, extended insulins
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
WO2008132224A3 (fr) * 2007-04-30 2009-03-19 Novo Nordisk As Procédé de déshydratation d'une composition de protéine, composition de protéine déshydratée et composition pharmaceutique contenant la protéine déshydratée
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
US9688737B2 (en) 2008-03-18 2017-06-27 Novo Nordisk A/S Protease stabilized acylated insulin analogues
US10259856B2 (en) 2008-03-18 2019-04-16 Novo Nordisk A/S Protease stabilized acylated insulin analogues
WO2010054403A1 (fr) 2008-11-10 2010-05-14 Alexion Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles associés au complément
EP2894166A1 (fr) 2008-11-10 2015-07-15 Alexion Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles associés à un complément
EP2894165A1 (fr) 2008-11-10 2015-07-15 Alexion Pharmaceuticals, Inc. Procédés et compositions pour le traitement de troubles associés à un complément
EP3121197A1 (fr) 2008-11-10 2017-01-25 Alexion Pharmaceuticals, Inc. Procédés et compositions de traitement de troubles associés à un complément
EP3101031A1 (fr) 2008-11-10 2016-12-07 Alexion Pharmaceuticals, Inc. Procédés et compositions de traitement de troubles associés à un complément
EP3974448A1 (fr) 2008-11-10 2022-03-30 Alexion Pharmaceuticals, Inc. Procédés et compositions de traitement de troubles associés à un complément
WO2010151526A1 (fr) 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Anticorps bispécifiques se liant aux protéines du complément
WO2011085343A1 (fr) 2010-01-11 2011-07-14 Alexion Pharmaceuticals, Inc Biomarqueurs d'effets immunomodulateurs chez des humains traités par des anticorps anti-cd200
US9221901B2 (en) 2010-04-30 2015-12-29 Alexion Pharmaceuticals, Inc. Methods of treating complement-associated disorders with anti-C5a antibodies
US9371378B1 (en) 2010-04-30 2016-06-21 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
US11407821B2 (en) 2010-04-30 2022-08-09 Alexion Pharmaceuticals, Inc. Anti-C5A antibodies
WO2011137395A1 (fr) 2010-04-30 2011-11-03 Rother Russell P Anticorps anti-c5a et méthodes pour utiliser les anticorps
US9434784B1 (en) 2010-04-30 2016-09-06 Alexion Pharmaceuticals, Inc. Nucleic acids encodng anti-C5A antibodies
US9469690B2 (en) 2010-04-30 2016-10-18 Alexion Pharmaceuticals, Inc. Methods of treating complement-associated disorders with anti-C5a antibodies
US9309310B2 (en) 2010-04-30 2016-04-12 Alexion Pharmaceuticals, Inc. Nucleic acids encoding anti-C5a antibodies
US10450370B2 (en) 2010-04-30 2019-10-22 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
EP2824111A2 (fr) 2010-04-30 2015-01-14 Alexion Pharmaceuticals, Inc. Anticorps anti-C5A et leurs procédés d'utilisation de ces anticorps
US9011852B2 (en) 2010-04-30 2015-04-21 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies
US9963503B2 (en) 2010-04-30 2018-05-08 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5a antibodies
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
EP3095795A1 (fr) 2014-03-07 2016-11-23 Alexion Pharmaceuticals, Inc. Anticorps anti-c5 présentant une pharmacocinétique améliorée
US10584164B2 (en) 2014-03-07 2020-03-10 Alexion Pharmaceuticals, Inc. Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies
US9079949B1 (en) 2014-03-07 2015-07-14 Alexion Pharmaceuticals, Inc. Anti-C5 antibodies having improved pharmacokinetics
US9663574B2 (en) 2014-03-07 2017-05-30 Alexion Pharmaceuticals, Inc. Anti-C5 antibodies having improved pharmacokinetics
US10227400B2 (en) 2014-03-07 2019-03-12 Alexion Pharmaceuticals, Inc. Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies
US9107861B1 (en) 2014-03-07 2015-08-18 Alexion Pharmaceuticals, Inc. Methods of treating C5 mediated complement-associated conditions with anti-C5 antibodies having improved pharmacokinetics
US11434280B2 (en) 2014-03-07 2022-09-06 Alexion Pharmaceuticals, Inc. Anti-C5 antibodies having improved pharmacokinetics
US9371377B2 (en) 2014-03-07 2016-06-21 Alexion Pharmaceuticals, Inc. Anti-C5 antibodies having improved pharmacokinetics
WO2015134894A1 (fr) 2014-03-07 2015-09-11 Alexion Pharmaceuticals, Inc. Anticorps anti-c5 présentant une pharmacocinétique améliorée
EP3594235A1 (fr) 2014-03-07 2020-01-15 Alexion Pharmaceuticals, Inc. Anticorps anti-c5 présentant une pharmacocinétique améliorée
US9803007B1 (en) 2014-03-07 2017-10-31 Alexion Pharmaceuticals, Inc. Anti-C5 antibodies having improved pharmacokinetics
US9206251B2 (en) 2014-03-07 2015-12-08 Alexion Pharmaceuticals, Inc. Nucleic acids encoding anti-C5 antibodies having improved pharmacokinetics
US10596231B2 (en) 2016-12-16 2020-03-24 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US10265385B2 (en) 2016-12-16 2019-04-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US11365241B2 (en) 2017-07-27 2022-06-21 Alexion Pharmaceuticals, Inc. High concentration anti-C5 antibody formulations
WO2019126536A1 (fr) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Anticorps humanisés anti-cd200 et leurs utilisations

Similar Documents

Publication Publication Date Title
WO2000061178A1 (fr) Administration pulmonaire de formulations de poudre seche pour le traitement de l'infecondite
AU779869B2 (en) Pulmonary administration of dry powder formulations for treating infertility
EP2152245B1 (fr) Procédé de déshydratation d'une composition de protéine, composition de protéine déshydratée et composition pharmaceutique contenant la protéine déshydratée
AU2014290438B2 (en) Heat-stable dry powder pharmaceutical compositions and methods
US7192919B2 (en) Sustained release compositions for delivery of pharmaceutical proteins
EP1462096B1 (fr) Methodes et compositions pour la délivrance pulmonale d'insulin
EP0951911A2 (fr) Méthode d'administration de aspb28-insuline humaine
US20110284412A1 (en) Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation
WO2000064940A1 (fr) Cristaux d'insuline destines a une administration pulmonaire
JP2008163033A (ja) エアゾール化医薬の肺への送達
CN1518441A (zh) 具有快速释放性质的吸入式微粒
EP1418890A1 (fr) Preparations de microparticules a base d'un agent propulseur
KR20150138428A (ko) Ｆｓｈ의 액체 포뮬레이션
EP1424066B1 (fr) Compositions sèches comprenant des stabilisateurs hydrophobes
WO2001093837A2 (fr) Poudre proteinique administree par voie pulmonaire
JP2005520847A (ja) 肺投与用ｈＧＨ（ヒト成長ホルモン）製剤
JP4699991B2 (ja) 非イオン性界面活性剤を一緒に伴うｆｓｈ及びｌｈの液体医薬組成物
EP2036572A1 (fr) Procédé pour le séchage d'une protéine, particule de protéine et composition pharmaceutique comprenant la particule de protéine
RU2175556C2 (ru) Способы и композиции для легочной доставки инсулина
US20040214747A1 (en) Method for administering monomeric insulin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2369262

Country of ref document: CA

Ref country code: CA

Ref document number: 2369262

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09958722

Country of ref document: US

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 610510

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000920245

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000920245

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642